ImmunoPrecise

67 articles about ImmunoPrecise

• ImmunoPrecise Antibodies Announces CFO Transition

  9/19/2023

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer.

• IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

  9/14/2023

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023.

• IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

  9/8/2023

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time.

• ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research

  7/14/2023

  ImmunoPrecise Antibodies Ltd. is delighted to extend an invitation to investors and other interested parties to participate in an upcoming interview hosted by Market Radius Research.

• ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

  7/7/2023

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023.

• IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

  6/13/2023

  ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma solution developed by its subsidiary, BioStrand®.

• IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market

  6/6/2023

  ImmunoPrecise Antibodies Ltd. introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and its subsidiary, BioStrand®.

• IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology

  5/30/2023

  ImmunoPrecise Antibodies Ltd. announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical data, 3D structural data, unstructured scientific information, and beyond - into a singular, integrated framework.

• IPA to Present at Jefferies Healthcare Conference 2023

  5/17/2023

  ImmunoPrecise Antibodies Ltd. today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

• ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

  3/23/2023

  Immunoprecise Antibodies Ltd. will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023.

• ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

  3/15/2023

  Immunoprecise Antibodies Ltd. today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular targets.

• IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023

  12/15/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal year 2023, which ended October 31, 2022.

• IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

  12/5/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time.

• IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

  11/30/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

• ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

  11/22/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares from the TSX Venture Exchange (“TSXV”).

• IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs

  10/12/2022

  IPA today announced that its subsidiary, Talem Therapeutics LLC (“Talem”), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated.

• IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023

  9/14/2022

  IPA (ImmunoPrecise ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022.

• IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022

  9/8/2022

  IPA, an advanced biotherapeutic research and technology company, announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time.

• IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

  7/26/2022

  IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022.

• Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2

  7/12/2022

  Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS ‑CoV‑2.